The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells.

OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options, particularly with immune checkpoint inhibitors. Highly chemoresistant 'stem-like' cells, known as cancer stem cells (CSCs), are implicated in PDAC aggressiveness. Thus, comprehending how this subset of cell...

Descripción completa

Detalles Bibliográficos
Autores: López-Gil, Juan Carlos, García-Silva, Susana, Ruiz-Cañas, Laura, Navarro, Diego, Palencia-Campos, Adrián, Giráldez-Trujillo, Antonio, Earl, Julie, Dorado, Jorge, Gómez-López, Gonzalo, Monfort-Vengut, Ana, Alcalá, Sonia, Gaida, Matthias M, García-Mulero, Sandra, Cabezas-Sáinz, Pablo, Batres-Ramos, Sandra, Barreto, Emma, Sánchez-Tomero, Patricia, Vallespinós, Mireia, Ambler, Leah, Lin, Meng-Lay, Aicher, Alexandra, García García de Paredes, Ana, de la Pinta, Carolina, Sanjuanbenito, Alfonso, Ruz-Caracuel, Ignacio, Rodríguez-Garrote, Mercedes, Guerra, Carmen, Carrato, Alfredo, de Cárcer, Guillermo, Sánchez, Laura, Nombela-Arrieta, César, Espinet, Elisa, Sanchez-Arevalo Lobo, Víctor Javier, Heeschen, Christopher, Sainz, Bruno
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/23079
Acceso en línea:https://hdl.handle.net/20.500.12105/23079
Access Level:acceso abierto
Palabra clave:Pancreatic Neoplasms
Neoplastic Stem Cells
Carcinoma, Pancreatic Ductal
Animals
Mice
Humans
Cell Line, Tumor
Tumor Escape
Disease Models, Animal
Immune Evasion
Tumor Microenvironment
Descripción
Sumario:OBJECTIVE: Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options, particularly with immune checkpoint inhibitors. Highly chemoresistant 'stem-like' cells, known as cancer stem cells (CSCs), are implicated in PDAC aggressiveness. Thus, comprehending how this subset of cells evades the immune system is crucial for advancing novel therapies. DESIGN: We used the KPC mouse model (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre) and primary tumour cell lines to investigate putative CSC populations. Transcriptomic analyses were conducted to pinpoint new genes involved in immune evasion. Overexpressing and knockout cell lines were established with lentiviral vectors. Subsequent in vitro coculture assays, in vivo mouse and zebrafish tumorigenesis studies, and in silico database approaches were performed. RESULTS: Using the KPC mouse model, we functionally confirmed a population of cells marked by EpCAM, Sca-1 and CD133 as authentic CSCs and investigated their transcriptional profile. Immune evasion signatures/genes, notably the gene peptidoglycan recognition protein 1 (PGLYRP1), were significantly overexpressed in these CSCs. Modulating PGLYRP1 impacted CSC immune evasion, affecting their resistance to macrophage-mediated and T-cell-mediated killing and their tumourigenesis in immunocompetent mice. Mechanistically, tumour necrosis factor alpha (TNF?)-regulated PGLYRP1 expression interferes with the immune tumour microenvironment (TME) landscape, promoting myeloid cell-derived immunosuppression and activated T-cell death. Importantly, these findings were not only replicated in human models, but clinically, secreted PGLYRP1 levels were significantly elevated in patients with PDAC. CONCLUSIONS: This study establishes PGLYRP1 as a novel CSC-associated marker crucial for immune evasion, particularly against macrophage phagocytosis and T-cell killing, presenting it as a promising target for PDAC immunotherapy.

Similares en LA Referencia